<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">

Orthotopic and Bioluminescent Models

Improve the predictive value of preclinical models with organ-specific TME and track disease progression in real time

Predictive Preclinical Benefits of Orthotopic Models

Orthotopic tumor models provide a clinically relevant, organ-specific tumor microenvironment (TME) to improve preclinical predictivity over subcutaneous alternatives. Generated by seeding tumor cells at the organ-specific site of the original tumor, orthotopic models mimic the primary lesion and establish better tumor, stroma, and immune component interactions than subcutaneous implantation.

This allows more human-disease relevant tumor development and progression, including spontaneous metastasis, recapitulating late-stage tumors. Orthotopic models therefore provide the ideal setting to:

  • investigate disease mechanisms
  • target the metastatic niche with new therapeutics
  • generate more patient-relevant response or resistance to anticancer agents.

Optical Imaging to Track Disease Progression and Metastasis

Orthotopic metastatic models are most powerful when the disease is tracked in vivo in real time by optical imaging of luciferase-labeled tumor cells.

comparing CCl4 NASH induction in conventional and MS-NASH dysmetabolic models

Figure 1: Luciferase-labeled model establishment by lentiviral transduction

Our collection of luciferase-labeled validated in vivo models allow you to non-invasively monitor the longitudinal growth of a tumor and to track tumor response to your treatment in real time, saving time and resources.

Advantages of Imaging Orthotopic Models

  • Amenable to large scale studies and high throughput 
  • Fast and efficient 2D imaging (3-5 animals at a time)
  • Simplified positive randomization and optimal treatment initiation on established tumors across all groups
  • Cost effective platform - reducing animal number per study and providing more data from each animal

Our cutting edge imaging techniques and platforms include:

  • 2D bioluminescence, multispectral fluorescence, and spectral unmixing
  • 3D optical tomography (IVIS® Spectrum)
  • Low dose and ultra-fast microCT (IVIS Spectrum/CT)
  • DyCE™ dynamic contrast enhanced imaging for real time distribution studies

Validated Bioluminescent Models


Our panel of orthotopic bioluminescent models include syngeneic as well as xenograft lines.

  • Choose orthotopic bioluminescent models to monitor your compound antitumor activity in real time using bioluminescent imaging, in the presence of a relevant TME.

  • Choose bioluminescent experimental metastasis models to mimic hard to develop late-stage disease, such as bone or brain metastases, and obtain patient-relevant information on the metastatic niche. These models are established by seeding bioluminescent tumor cells either i.v. to facilitate lodging at the metastatic site, or directly into the organ where clinical metastases have been seen.

  • Choose bioluminescent systemic models for an easier monitoring of tumor burden and response to treatment in absence of palpable solid tumors via real time longitudinal imaging.

Table 1: Available bioluminescent models (additional models under development and can be developed upon client request)

Orthotopic Models

Cancer Type human Cell Line (implantation site/route) Mouse cell line (implantation site/route)
Brain U-87 MG-luc  
Breast MDA-MB-231-luc* (MFP),
MCF-7-luc (MFP)
4T1-luc (MFP with mets to lung)
Hepatoma HEP 3B-luc H22-luc,
Hepa 1-6-luc
Lung A549-luc (i.v.)  
Multiple Myeloma MM.1S-luc (i.tb),
RPMI822-luc (i.tb.)
Ovarian A2780-luc (i.p.),
SK-OV-3-luc (i.p.)
Prostate PC-3M-luc*  

Systemic Models

Cancer Type Human Cell Line (implantation site/route) Mouse cell line (implantation site/route)
Leukemia MV-4-11-luc (i.v.),
Nalm6-luc (i.v.)
Lymphoma Raji-luc (i.v.),
Raji-PD-L1-luc (i.v.)
Multiple Myeloma M.1S-luc (i.v.)  

Experimental Metastasis Models

Cancer Type Human Cell Line (implantation site/route) Mouse cell line (implantation site/route)
Lung A549-luc (i.v.)  
Breast MDA-MB-231-luc* (i.c.)  

*Client license required
Models provided by sponsor but the right of use has been granted (not fit for CFDA studies)

Discuss your Orthotopic and Bioluminescent Models Project

Tell us how we can help!

Talk To Us